Request Demo
Last update 08 May 2025
ThisCART19A(Zhejiang University)
Last update 08 May 2025
Overview
Basic Info
Drug Type Universal CAR-T |
Synonyms- |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), T lymphocyte replacements |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
6
Clinical Trials associated with ThisCART19A(Zhejiang University)NCT06212154
The Safety and Efficacy of ThisCART19A for Relapsed/Refractory Autoimmune Hemolytic Anemia Patients After Receiving Three or More Lines of Therapy.
NCT05535673
A Single Dose-escalation Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Allogeneic CAR-T Targeting CD19 in Patients With Refractory or Relapsed B Cell Lymphoma
NCT05350787
To Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Relapsed and Refractory Acute B-cell Leukemia
100 Clinical Results associated with ThisCART19A(Zhejiang University)
Login to view more data
100 Translational Medicine associated with ThisCART19A(Zhejiang University)
Login to view more data
100 Patents (Medical) associated with ThisCART19A(Zhejiang University)
Login to view more data
100 Deals associated with ThisCART19A(Zhejiang University)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Autoimmune Haemolytic Anaemias | Phase 1 | China | 20 Jan 2024 | |
| CD19 positive B-Cell Lymphoma | Phase 1 | - | 02 Sep 2022 | |
| Diffuse Large B-Cell Lymphoma | Phase 1 | - | 02 Sep 2022 | |
| AIDS-Related Lymphoma | Phase 1 | China | 18 Mar 2022 | |
| CD19-positive B-cell acute lymphoblastic leukemia | Phase 1 | China | 18 Mar 2022 | |
| Pre B-cell acute lymphoblastic leukemia | Phase 1 | China | 18 Mar 2022 | |
| Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | China | 18 Mar 2022 | |
| Refractory B Acute Lymphoblastic Leukemia | Phase 1 | China | 18 Mar 2022 | |
| Residual Neoplasm | Phase 1 | China | 18 Mar 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 10 | (asnuyomzxt) = fxdezepvlb jiyzcgmxrp (gftwlzuzkk ) View more | - | 09 Dec 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free